60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model
$1.97 million cash on hand, runway through March 31, 2026
WASHINGTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today its financial results for the second quarter of 2025, ended June 30, 2025.
While net product revenues declined compared to Q2 2024 due to a now resolved supply chain disruption, the Company reported an increase in profitability, largely attributed to cash-pay patients using KODATEF® (tafenoquine) 16-count boxes which were imported with U.S. Food and Drug Administration (FDA) consent to help mitigate a temporary disruption of supply of ARAKODA® 16-count boxes.
Provided the Company reaches minimum enrollment in its hospitalized babesiosis study prior to the end of the 2025 tick season in early October, the Company's current cash position is expected to allow the trial's interim analysis to be conducted prior to the need for additional capital.
Financial Highlights:
Q2 2025 net product revenues decreased 19% year-over-year from $125 thousand to $101 thousand. This was associated with a decrease of 17% in ARAKODA pharmacy deliveries, from 1,301 boxes (Q2 2024) to 1,082 16-count box equivalents (Q2 2025). This occurred due to a temporary disruption of supply of ARAKODA 16-count boxes which was incompletely mitigated by the introduction of the new 8-count ARAKODA bottle, and importation, with FDA consent, of KODATEF (tafenoquine 16-count boxes). New commercial lots of ARAKODA 16-count boxes are anticipated to enter the supply chain in September, 2025.
The Company achieved a gross profit of approximately $51 thousand in the second quarter of 2025, compared to an approximate gross profit of $35 thousand in the second quarter of 2024. This was primarily due to lower overall cost of sales and via the sale of KODATEF 16-count boxes (which had fewer discounts/rebates).
Operating expenses were approximately $1.86 million in the second quarter of 2025, compared to approximately $4.22 million in the second quarter of 2024. This was primarily due to the absence of one-off, non-cash, research and development costs that occurred ...
